• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule

    10/31/24 7:00:00 AM ET
    $CIA
    $EUDA
    $GOSS
    $LDTC
    Life Insurance
    Finance
    Medical/Nursing Services
    Health Care
    Get the next $CIA alert in real time by email

    MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces NRx Pharmaceuticals (NASDAQ:NRXP) will appear on the Emerging Growth Conference today in response to multiple requests and investor demand.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Jonathan Javitt, MD, MPH, Founder and Chairman will be discussing its first steps towards acquisition through its HOPE Therapeutics subsidiary of a national network of interventional psychiatry clinics focused on treatment of suicidal depression and PTSD with ketamine, transcranial magnetic stimulation, digital therapeutics, and other therapies that affect the NMDA receptor of the brain.

    NRx Pharmaceuticals will be presenting on October 31st from 11:25 to 11:55 eastern time.

    Register for the NRx Pharmaceuticals Conference here.

    Submit Questions for NRx Pharmaceuticals, Inc. to:

    [email protected]

    For updates, follow us on Twitter

    Updates to the Day 2 Schedule:

    10:30

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    10:45

    Introduction

    10:50 – 11:20

    Monumental Energy Corp. (OTCQB:MNMRF) (TSXV:MNRG)

    Keynote speaker: Maximilian Sali – VP Corporate Development Founder & Director

    11:25 – 11:55

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)

    Keynote speaker: Dr. Jonathan C. Javitt, Chairman and Interim CEO.

    12:00 - 12:30

    Vox Royalty Corp. (NASDAQ:VOXR) (TSX:VOXR)

    Keynote speakers: Kyle Floyd, Chairman & CEO & Chief Investment Officer

    12:35 – 1:05

    Stuhini Explorations, Ltd. (OTCQB:STXPF) (TSXV:STU)

    Keynote speaker: David O'Brien, President & CEO

    1:10 - 1:40

    Bioxytran, Inc. (OTCQB:BIXT)

    Keynote speakers: Mike Sheikh, Executive Vice President Business Development

    2:25 – 2:35

    Citizens, Inc. (NYSE:CIA)

    Keynote speakers: Jon Stenberg, President & CEO, and Jeff Conklin, CFO

    2:40 – 2:50

    Gossamer Bio, Inc. (NASDAQ:GOSS)

    Keynote speaker: Bryan Giraudo, CFO & COO

    2:55 – 3:05

    Interstellar Communication Holdings

    Keynote speakers: Seda Hewitt, Space Ambassador of IcMercury Harri Laitinen, Lifeguard of IcMercury, and Lijie Zhu, Capitan of icMercury

    3:10 - 3:20

    Sono Group N.V. (OTCQB:SEVCF)

    Keynote speaker: George O'Leary, Managing Director, CEO and CFO

    3:25 - 3:35

    Cyios Corp. (OTC:CYIO)

    Keynote speaker: John O'Shea, Chairman

    3:40 – 3:50

    NurExone Biologic Inc. (OTCQB:NRXBF) (TSXV:NRX)

    Keynote speaker: Dr. Lior Shaltiel, CEO

    3:55 – 4:05

    Evanesce

    Keynote speaker: Douglas Horne, Founder & CEO

    4:10 – 4:20

    LeddarTech Holdings, Inc. (NASDAQ:LDTC)

    Keynote speakers: Frantz Saintellemy – CEO & Chris Stewart, CFO

    4:25 – 4:35

    NCS Multistage Holdings, Inc. (NASDAQ:NCSM)

    Keynote speaker: Ryan Hummer, CEO & Director

    4:40 – 4:50

    EUDA Health Holdings Limited, (NASDAQ:EUDA)

    Keynote speaker: Kelvin Chen, CEO

    About NRx Pharmaceuticals, Inc.

    NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a healthcare delivery company developing the nation's first network of interventional psychiatry clinics targeting suicidal depression and PTSD through the use of ketamine, transcranial magnetic stimulation, digital therapeutics, and other therapies that target the brain's NMDA receptor. HOPE is committed to offering state of the art lifesaving therapy to the more than 3.4 million Americans who grapple with suicidal depression each year.

    Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

    Register for the NRx Pharmaceuticals Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: [email protected]



    Primary Logo

    Get the next $CIA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • When and where will NRx Pharmaceuticals be presenting?

      NRx Pharmaceuticals (NASDAQ: NRXP) is set to present at the Emerging Growth Conference on October 31, 2024, at 11:25 AM to 11:55 AM Eastern Time.

    • Who will be the keynote speaker for NRx Pharmaceuticals at the conference, and what will be the focus of their presentation?

      Jonathan Javitt, MD, MPH, Founder and Chairman of NRx Pharmaceuticals, will discuss the company's acquisition strategies and the treatments being developed for suicidal depression and PTSD.

    • What is the purpose of the Emerging Growth Conference?

      The Emerging Growth Conference aims to connect small-cap companies with investors and highlights companies with strong management teams and innovative products.

    • What type of health conditions does NRx Pharmaceuticals aim to address with its therapeutics?

      NRx Pharmaceuticals focuses on treating central nervous system disorders, particularly suicidal bipolar depression, chronic pain, and PTSD, through its NMDA platform.

    • What is the role of HOPE Therapeutics in NRx Pharmaceuticals' strategy?

      HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, is planning to establish a national network of interventional psychiatry clinics specializing in advanced psychiatric treatments.

    Recent Analyst Ratings for
    $CIA
    $EUDA
    $GOSS
    $LDTC

    CompanyDatePrice TargetRatingAnalyst
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Neutral
    Wedbush
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$0.30Overweight → Equal Weight
    Barclays
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Market Perform
    Leerink Partners
    Gossamer Bio Inc.
    $GOSS
    1/28/2026$9.00Overweight
    Barclays
    Gossamer Bio Inc.
    $GOSS
    9/10/2025$9.00Neutral → Buy
    UBS
    NRX Pharmaceuticals Inc.
    $NRXP
    9/8/2025$40.00Buy
    H.C. Wainwright
    Gossamer Bio Inc.
    $GOSS
    7/14/2025$11.00Sector Outperform
    Scotiabank
    NRX Pharmaceuticals Inc.
    $NRXP
    4/2/2025$18.00Buy
    BTIG Research
    More analyst ratings

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Gossamer Bio downgraded by Wedbush with a new price target

    Wedbush downgraded Gossamer Bio from Outperform to Neutral and set a new price target of $1.00

    2/24/26 8:01:18 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio downgraded by Barclays with a new price target

    Barclays downgraded Gossamer Bio from Overweight to Equal Weight and set a new price target of $0.30

    2/24/26 7:42:57 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Gossamer Bio from Outperform to Market Perform and set a new price target of $1.00

    2/24/26 7:42:57 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CIA
    $EUDA
    $GOSS
    $LDTC
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Gossamer Bio Inc.

    SCHEDULE 13G - Gossamer Bio, Inc. (0001728117) (Subject)

    3/2/26 11:57:56 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by EUDA Health Holdings Limited

    6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

    3/2/26 8:30:27 AM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    SEC Form 424B5 filed by EUDA Health Holdings Limited

    424B5 - EUDA Health Holdings Ltd (0001847846) (Filer)

    3/2/26 8:01:26 AM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Casper Joseph Michael

    4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    2/17/26 7:00:43 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Casper Joseph Michael

    3 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    2/17/26 7:00:15 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Taylor Mary increased direct ownership by 1% to 48,364 units (SEC Form 5)

    5 - CITIZENS, INC. (0000024090) (Issuer)

    1/30/26 10:29:36 AM ET
    $CIA
    Life Insurance
    Finance

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

    Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders. WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, P

    3/2/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NCS Multistage Holdings, Inc. Schedules Fourth Quarter 2025 Earnings Release and Conference Call

    HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- NCS Multistage Holdings, Inc. ("NCS" or the "Company") (NASDAQ:NCSM) will host a conference call to discuss its fourth quarter 2025 results on Thursday, March 5, 2026 at 7:30 a.m. Central Time (8:30 a.m. Eastern Time). NCS will issue its fourth quarter 2025 earnings release the evening prior to the conference call. The conference call will be available via a live audio webcast. Participants who wish to ask questions may register for the call here to receive the dial-in numbers and unique PIN. If you wish to join the conference call but do not plan to ask questions, you may join the listen-only webcast here. It is recommended that participants joi

    2/25/26 5:42:44 PM ET
    $NCSM
    Oilfield Services/Equipment
    Energy

    Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

    - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - - At week 24, patients receiving seralutinib had a median change of +28.2 meters from baseline, while patients receiving placebo had a median change from baseline of +13.5 meters - - Consistent with the TORREY Study, prespecified intermediate and high-risk subgroup (n = 234) showed a +20.0 meter placebo-adjusted 6MWD improvement (p = 0.0207), with 3 of 4 key secondary endpoints achieving p < 0.0125 - - Overall treatment effect was most pronounced in North America (n = 75), with a +25.9m placebo-adjuste

    2/23/26 8:00:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Milligan Sandra bought $50,016 worth of shares (26,050 units at $1.92), increasing direct ownership by 81% to 58,050 units (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    8/20/25 4:04:35 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Stenberg Jon bought $66,407 worth of Citizens (19,914 units at $3.33), increasing direct ownership by 11% to 198,930 units (SEC Form 4)

    4 - CITIZENS, INC. (0000024090) (Issuer)

    6/18/25 2:42:21 PM ET
    $CIA
    Life Insurance
    Finance

    President & CEO Stenberg Jon bought $129,268 worth of Citizens (34,850 units at $3.71), increasing direct ownership by 20% to 179,016 units (SEC Form 4)

    4 - CITIZENS, INC. (0000024090) (Issuer)

    6/2/25 9:53:01 AM ET
    $CIA
    Life Insurance
    Finance

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

    SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

    11/12/24 4:40:26 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

    SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

    11/12/24 9:55:14 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by LeddarTech Holdings Inc.

    SC 13D/A - LeddarTech Holdings Inc. (0001981462) (Subject)

    8/26/24 1:10:05 PM ET
    $LDTC
    Computer Software: Prepackaged Software
    Technology

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Leadership Updates

    Live Leadership Updates

    View All

    NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

    Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders. WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, P

    3/2/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director

    Cohen and Associates has more than a decade of leadership in interventional psychiatry and Transcranial Magnetic Stimulation (TMS) Dr. Rebecca Cohen has joined HOPE as Medical DirectorImmediate expansion is planned in Western Florida and Palm BeachAcquisition expected to be accretive to HOPE Therapeutics revenue and EBITDA MIAMI, Oct. 20, 2025 (GLOBE NEWSWIRE) -- HOPE Therapeutics™, Inc. ("HOPE"), an interventional psychiatry network owned by NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), today announced the acquisition of a strategic interest in Cohen and Associates, LLC ("Cohen, LLC") and its incorporation into the HOPE Network. Additionally, Rebecca Cohen, MD has joined HOPE as Medical Dire

    10/20/25 8:03:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join Fireside Chat at BTIG Virtual Biotech Conference July 29 - 30, 2025

    WILMINGTON, Del., July 29, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", or the "Company"), today announced that its CEO and Chairman will join a fireside chat at BTIG Virtual Biotechnology Conference on July 29 – 30, 2025. Prof. Jonathan Javitt, MD, MPH will join Prof. Samuel Wilkinson, MD, of the Yale School of Medicine, and  BTIG Research Analyst Dr. Thomas Shrader for a fireside chat to discuss neuroplasticity in the treatment of CNS disorders at 8:00 a.m. EDT on Wednesday, July 30, 2025. Prof. Wilkinson is a widely published psychiat

    7/29/25 8:03:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Financials

    Live finance-specific insights

    View All

    NCS Multistage Holdings, Inc. Schedules Fourth Quarter 2025 Earnings Release and Conference Call

    HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- NCS Multistage Holdings, Inc. ("NCS" or the "Company") (NASDAQ:NCSM) will host a conference call to discuss its fourth quarter 2025 results on Thursday, March 5, 2026 at 7:30 a.m. Central Time (8:30 a.m. Eastern Time). NCS will issue its fourth quarter 2025 earnings release the evening prior to the conference call. The conference call will be available via a live audio webcast. Participants who wish to ask questions may register for the call here to receive the dial-in numbers and unique PIN. If you wish to join the conference call but do not plan to ask questions, you may join the listen-only webcast here. It is recommended that participants joi

    2/25/26 5:42:44 PM ET
    $NCSM
    Oilfield Services/Equipment
    Energy

    Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

    - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - - At week 24, patients receiving seralutinib had a median change of +28.2 meters from baseline, while patients receiving placebo had a median change from baseline of +13.5 meters - - Consistent with the TORREY Study, prespecified intermediate and high-risk subgroup (n = 234) showed a +20.0 meter placebo-adjusted 6MWD improvement (p = 0.0207), with 3 of 4 key secondary endpoints achieving p < 0.0125 - - Overall treatment effect was most pronounced in North America (n = 75), with a +25.9m placebo-adjuste

    2/23/26 8:00:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call

    WILMINGTON, Del., Dec. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a corporate update conference call on Tuesday, December 2, 2025 at 9:00am ET. The call will provide a corporate update, including recent clinical, regulatory, and operational developments. A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-800-717-1738 or internationally 1-646-307-1865. About NRx P

    12/2/25 7:30:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care